11月20日，多氟多跌5.02%，截至发稿，报36.11元/股，成交43.59亿元，换手率10.77%，总市值429.87 亿元。 资料显示，多氟多新材料股份有限公司位于河南省焦作市中站区焦克路，成立日期1999年12月21日，上 市日期2010年5月18日，公司主营业务涉及六氟磷酸锂及电子化学品、锂离子电池、新能源汽车、无机 氟化盐。主营业务收入构成为：新能源材料34.97%，氟基新材料30.39%，新能源电池25.30%，电子信 息材料5.55%，其他3.80%。 截至发稿，冷文鹏累计任职时间9年163天，现任基金资产总规模13.31亿元，任职期间最佳基金回报 236.32%， 任职期间最差基金回报-21.77%。 从基金十大重仓股角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 数据显示，中信建投基金旗下1只基金重仓多氟多。中信建投价值增长混合A（025231）三季度持有股 数105.77万股，占基金净值比例为2.56%，位居第九大重仓股。根据测算，今日浮亏损失 ...

东吴证券表示，行业内的资源整合或将成为券商快速提升规模与综合实力的又一重要方式。大型券商通 过并购进一步补齐短板，巩固优势，中小券商通过外延并购有望弯道超车，快速做大，实现规模效应和 业务互补。 中信建投指出，证券行业当前配置价值提升的核心逻辑在于政策、资金及自身转型的三方面支撑。政策 端，"活跃资本市场"导向明确，注册制深化、交易机制优化、引入中长期资金等举措持续落地，直接拓 宽了券商投行、经纪、资管等业务空间。资金端，市场信心修复带动成交回暖与两融回升，叠加养老 金、保险等增量资金入市可期，为券商业绩提供弹性基础。自身转型方面，行业正着力发展高附加值业 务，尤其是财富管理和机构业务，优化收入结构并增强盈利稳定性。券商不仅受益于市场回暖的Beta弹 性，更因成功转型而具备独特的Alpha增长潜力（盈利质量提升）。政策预期、资金改善与内生动力共 同作用，使得券商板块的盈利前景确定性提升，当前具备较高的配置吸引力。 消息面上，11月19日晚，中金公司、东兴证券、信达证券发布《关于筹划重大资产重组的停牌公告》， 三家公司正在筹划由中金公司通过向东兴证券全体A股换股股东发行A股股票、向信达证券全体A股换 股股东发行 ...

疫苗：经营持续承压，期待销售环比改善及新品贡献 1)看好创新品种未来格局，建议关注创新疫苗管线研发进展。2)政策方面：近期商业保险、医防融合及 行业并购相关政策陆续出台，为疫苗行业未来发展奠定了政策基础，期待后续进展。3)疫苗行业出海： 随着疫苗企业出海事业持续推进，出海动作也在价值链上下游加速延展深化，期待各企业海外市场开拓 进展。4)国资入主持续赋能，关注后续进展。 医药零售：转型变革稳步推进，关注多元催化 智通财经APP获悉，中信建投发布研报称，中药行业短期基数压力有望缓解，渠道库存加速出清，看好 年底需求回暖，及后续基本面和估值改善机会;创新领域有助构建第二增长曲线，中药消费品公司品牌 延展空间广阔。血制品行业关注"十五五"浆站建设规划及行业并购整合进展，需求端看好静丙、因子类 产品需求端提升及新品研发。疫苗行业关注重磅产品销售改善情况及创新管线研发进展，政策出台及疫 苗出海有望推动企业进一步发展。医药零售行业转型变革稳步推进，关注后续多元催化。医药流通行业 收入端稳健向好，关注回款及"十五五"规划。 中信建投主要观点如下： 中药：着眼长期，静待改善 1)短期行业基数压力有望逐步缓解，渠道调整加速出清 ...

| 代码 | 名称 | | 涨跌幅 √ | 最新价 | 总市值 | 年初至今涨跌 | | --- | --- | --- | --- | --- | --- | --- | | 06881 | 中国银河 | | 4.62% | 11.090 | 1212.63亿 | 64.58% | | 03958 | 东方证券 | | 4.46% | 7.500 | 637.25 Z | 55.61% | | 06178 | 光大证券 | | 4.41% | 9.710 | 447.71亿 | 25.11% | | 06806 | 申万宏源 | | 4.08% | 3.320 | 831.33亿 | 49.46% | | 01375 | 中州证券 | | 3.91% | 2.390 | 110.96亿 | 41.20% | | 06066 | 中信建投证券 | | 3.61% | 12.900 | 1000.61亿 | 33.83% | | 06030 | 中信证券 | | 3.25% | 28.580 | 4235.71亿 | 35.81% | | 06886 | 华泰证券 | | 2.75% | 19.400 | 17 ...

Market Overview - The market experienced narrow fluctuations yesterday, with both the Shanghai Composite Index and the ChiNext Index closing in the green. The total trading volume in the Shanghai and Shenzhen markets was 1.73 trillion, a decrease of 200.2 billion compared to the previous trading day [1]. Sector Performance - The sectors that saw the highest gains included precious metals, military industry, and aquaculture, while sectors such as Hainan, gas, and film and television box office experienced declines. By the end of the trading day, the Shanghai Composite Index rose by 0.18%, and the ChiNext Index increased by 0.25% [1]. Investment Recommendations Huatai Securities - Huatai Securities continues to recommend cyclical aviation, trading in oil transportation, and allocation in highways. The firm notes that external uncertainties have settled, leading to a recovery in industrial production and export sentiment, along with a mild rebound in consumer data. Specifically, they expect: 1. Aviation: October ticket prices continue to improve, supported by low supply growth and a low base, indicating a sustained recovery in industry profitability. 2. Oil Transportation: Multiple favorable factors, including OPEC+/U.S. production increases and low oil prices, are expected to maintain high activity levels in the oil transportation sector. 3. Highways: With insurance funds beginning year-end allocations, the highway sector is anticipated to have upward potential due to attractive dividend yields [2]. CITIC Securities - CITIC Securities is optimistic about the traditional Chinese medicine industry, anticipating a recovery in demand by year-end and subsequent improvements in fundamentals and valuations. They highlight: - The easing of short-term base pressure and accelerated channel inventory clearance. - The potential for innovative areas to create a second growth curve, with significant brand extension opportunities for Chinese medicine consumer goods. - Attention to the blood products sector regarding the "14th Five-Year Plan" for plasma stations and industry consolidation, as well as the vaccine sector's product sales and innovation pipeline [3]. Tianfeng Securities - Tianfeng Securities suggests focusing on the recovery opportunities in the liquor sector, noting a "volume increase, price drop" trend during the 2025 Double Eleven shopping festival. Key points include: - Traditional e-commerce platforms saw major liquor prices fall below critical levels due to inventory pressures, while emerging channels like instant retail and Douyin experienced growth. - Liquor companies are actively combating counterfeiting and stabilizing prices through authorized and unauthorized listings. - The industry is shifting from price wars to value reconstruction, emphasizing high-quality products and refined channel operations. The current dividend returns from leading liquor companies are attractive, and consumer spending is expected to gradually recover [4].

人民财讯11月20日电，中信建投（601066）发布医药生物2026年投资策略：中国医药产业迈入"创新兑 现+全球布局"的关键阶段，人口与内需基数、全产业链制造能力构成核心支撑，企业积极探索多元化 的出海路径。面对全球竞争与政策深化，行业需"立足于内、创新引领、开拓于外"，对内强化供应链安 全与合规能力，对外深化多元化出海布局。展望2026年，重点把握创新商业化、全球化突破、政策优化 带来的新增量及行业并购整合的机遇。 ...

人民财讯11月20日电，中信建投（601066）研报称，11月12日至16日，COA骨科学术大会在天津召 开，会议聚焦骨科数字技术与智能手段，展区吸引上百家顶尖医疗器械厂商与创新企业参展，展品范围 全面覆盖骨科植入物、手术机器人、智能诊疗设备、生物材料及术后康复等全产业链最新产品与技术。 短期来看，骨科三大细分领域集采均逐渐出清，各家公司经营业绩也陆续迎来拐点。中长期来看，骨科 集采后国产厂商的份额有望提升、行业集中度也有望持续提升，随着老龄化加剧，骨科手术渗透率持续 提升，骨科耗材公司布局手术机器人业务，有望带动植入物耗材放量，打造设备+耗材的闭环商业模 式；同时，相关公司也在积极出海，有望打开成长天花板。 ...

智通财经APP获悉，中信建投证券发布研报称，11月以来，金价与纳指多次同涨同跌，二者分属避险和 风险资产，其相关性上升，引发更深层次风险的担忧。货币市场流动性冲击，不太可能是主要原因。近 期，随着月末扰动、美国政府关门等因素消退，资金利率已经回落，压力边际缓解。 幕后推手可能是复苏预期下的联储紧缩担忧。美联储政策的方向性变化，往往造成大类资产在短期的统 一走势。近期，出现复苏和再通胀预期（减税、降息、贸易缓和等），降息预期收敛，叠加科技公司深 陷债务融资质疑，黄金和纳指均遭受利空，相关性上升。 实际上，上述现象不局限在黄金和纳指的范畴内，大类资产整体的趋同性，在近期均有所加强。选取全 球常见的股债汇商等资产，计算其相关性水平，显示：10月以来，整体资产正向关联水平持续上升，11 月后，处于过去两年的偏高水平，且保持在历史均值之上。因此，纳指和黄金的同涨同跌，可能不是孤 立现象，而是更广泛存在。 货币市场趋紧、资金利率走高带来的流动性冲击，不太可能是主要原因。在11月第一周，美股开始调 整，黄金也未能幸免，市场普遍将原因归咎于流动性危机，当时短端资金利率出现明显抬升，政府关门 导致财政存款激增、商业银行准备金骤 ...

Group 1 - The short-term pressure on the traditional Chinese medicine industry is expected to ease, with channel inventory clearing accelerating, leading to a positive outlook for year-end demand recovery and subsequent fundamental and valuation improvement opportunities [1] - The innovative sector is expected to help build a second growth curve, with significant brand extension potential for traditional Chinese medicine consumer companies [1] - In the blood products industry, attention is focused on the "14th Five-Year Plan" for plasma station construction and industry merger and acquisition progress, with an optimistic view on the demand for immunoglobulin and factor products, as well as new product development [1] Group 2 - In the vaccine industry, the focus is on the sales improvement of key products and the progress of the innovation pipeline, with policy implementation and international expansion expected to further drive corporate development [1] - The transformation and reform in the pharmaceutical retail industry is steadily advancing, with attention on subsequent multi-faceted catalysts [1] - The pharmaceutical distribution industry shows stable revenue growth, with a focus on receivables and the "14th Five-Year Plan" [1]

Core Viewpoint - The 2025 China Securities Industry Asset Management Summit highlighted the evolving landscape of the asset management industry, emphasizing the need for innovation and adaptation in response to market changes and new demands [2][3]. Group 1: Industry Trends - The asset management industry in China is experiencing a transformation with a more rational business structure and enhanced operational standards, leading to increased competitiveness [2]. - Three major trends are reshaping the securities asset management ecosystem: digital empowerment through AI and large model technologies, upgraded demand for innovative products like retirement and green investments, and a shift from traditional investment management to comprehensive solution providers [2][3]. Group 2: Challenges and Strategies - The asset management sector faces significant challenges, including asset scarcity, low interest rates, and high volatility, necessitating a transition from a single high-yield asset model to a multi-strategy approach [3]. - Firms must focus on brand cultivation and long-term development while enhancing active management capabilities and customer service to meet market demands effectively [3]. Group 3: Forum Highlights - The forum featured two roundtable discussions addressing opportunities and challenges in the post-public offering era and strategies for product layout in a low-interest-rate environment [4]. - The "2025 China Securities Industry Asset Management Jun Ding Award" was announced, recognizing outstanding contributions in the asset management field [4][6].